Literature DB >> 18633565

Levosimendan for bridging in a pediatric patient with Alström syndrome awaiting heart-lung transplantation.

Marc-Phillip Hitz, Harald Bertram, Harald Köditz, Heidi Görler, Christoph M Happel, Armin Wessel, T Mesud Yelbuz.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18633565     DOI： 10.1007/s00392-008-0691-4

Source DB:  PubMed          Journal:  Clin Res Cardiol        ISSN： 1861-0684            Impact factor:   5.460


× No keyword cloud information.
  6 in total

1.  Retinal degeneration combined with obesity, diabetes mellitus and neurogenous deafness: a specific syndrome (not hitherto described) distinct from the Laurence-Moon-Bardet-Biedl syndrome: a clinical, endocrinological and genetic examination based on a large pedigree.

Authors:  C H ALSTROM; B HALLGREN; L B NILSSON; H ASANDER
Journal:  Acta Psychiatr Neurol Scand Suppl       Date:  1959

Review 2.  Evidence-based use of levosimendan in different clinical settings.

Authors:  Leonardo De Luca; Wilson S Colucci; Markku S Nieminen; Barry M Massie; Mihai Gheorghiade
Journal:  Eur Heart J       Date:  2006-04-27       Impact factor: 29.983

3.  Early experience with Levosimendan in children with ventricular dysfunction.

Authors:  Poongundran Namachivayam; David S Crossland; Warwick W Butt; Lara S Shekerdemian
Journal:  Pediatr Crit Care Med       Date:  2006-09       Impact factor: 3.624

4.  Levosimendan for low cardiac output: a pediatric experience.

Authors:  Jonathan R Egan; Andrew J B Clarke; Stephen Williams; Andrew D Cole; Julian Ayer; Stephen Jacobe; Richard B Chard; David S Winlaw
Journal:  J Intensive Care Med       Date:  2006 May-Jun       Impact factor: 3.510

5.  Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE Randomized Trial.

Authors:  Alexandre Mebazaa; Markku S Nieminen; Milton Packer; Alain Cohen-Solal; Franz X Kleber; Stuart J Pocock; Roopal Thakkar; Robert J Padley; Pentti Põder; Matti Kivikko
Journal:  JAMA       Date:  2007-05-02       Impact factor: 56.272

6.  Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial.

Authors:  F Follath; J G F Cleland; H Just; J G Y Papp; H Scholz; K Peuhkurinen; V P Harjola; V Mitrovic; M Abdalla; E-P Sandell; L Lehtonen
Journal:  Lancet       Date:  2002-07-20       Impact factor: 79.321
  6 in total
  3 in total

1.  Effect of levosimendan and predictors of recovery in patients with peripartum cardiomyopathy, a randomized clinical trial.

Authors:  Murat Biteker; Nilüfer Ekşi Duran; Hasan Kaya; Sabahattin Gündüz; Halil Îbrahim Tanboğa; Tayyar Gökdeniz; Gökhan Kahveci; Taylan Akgün; Mustafa Yildiz; Mehmet Õzkan
Journal:  Clin Res Cardiol       Date:  2011-01-01       Impact factor: 5.460

Review 2.  Alström syndrome: insights into the pathogenesis of metabolic disorders.

Authors:  Dorothée Girard; Nikolai Petrovsky
Journal:  Nat Rev Endocrinol       Date:  2010-12-07       Impact factor: 43.330

Review 3.  Tako-Tsubo syndrome: dying of a broken heart?

Authors:  Ch Sinning; T Keller; N Abegunewardene; K-F Kreitner; T Münzel; S Blankenberg
Journal:  Clin Res Cardiol       Date:  2010-09-17       Impact factor: 5.460
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.